​

Trevi Therapeutics (TRVI) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChartTranscripts

TRVI Stock Forecast

Trevi Therapeutics (TRVI) stock forecast, based on 18 Wall Street analysts, predicts a 12-month average price target of $29.67, with a high of $40.00 and a low of $23.00. This represents a 135.29% increase from the last price of $12.61.

$10 $16 $22 $28 $34 $40 High: $40 Avg: $29.67 Low: $23 Last Closed Price: $12.61

TRVI Stock Rating

Trevi Therapeutics stock's rating consensus is Buy, based on 18 Wall Street analysts. The breakdown includes 1 Strong Buy (5.56%), 17 Buy (94.44%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 18 0 17 1 Strong Sell Sell Hold Buy Strong Buy

TRVI Price Target Upside V Benchmarks

TypeNameUpside
StockTrevi Therapeutics135.29%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-311
Avg Price Target-$29.33$25.00
Last Closing Price$12.61$12.61$12.61
Upside/Downside-132.59%98.26%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 2628---10
Sep, 2629---11
Aug, 2629---11
Jul, 2628---10
Jun, 2628---10
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 07, 2026Morgan Stanley$23.00$18.2326.17%82.39%
Aug 07, 2026Oppenheimer$25.00$18.2536.99%98.26%
Aug 07, 2026Ryan DeschnerRaymond James$40.00$18.50116.22%217.21%
Jul 20, 2026BMO Capital$36.00$16.77114.67%185.49%
Jul 20, 2026Brandon FolkesH.C. Wainwright$24.00$19.0725.85%90.33%
May 08, 2026Annabel SamimyStifel Nicolaus$30.00$14.05113.52%137.91%
May 06, 2026Morgan Stanley$20.00$14.6636.43%58.60%
Dec 19, 2025Stifel Nicolaus$18.00$12.1947.66%42.74%
Nov 19, 2025Roanna RuizLeerink Partners$16.00$11.3141.47%26.88%
Nov 14, 2025Judah FrommerMorgan Stanley$19.00$11.6862.67%50.67%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 07, 2026BMO CapitalOutperformOutperformhold
Sep 25, 2026OppenheimerOutperformOutperformhold
Aug 07, 2026Morgan StanleyOverweightOverweighthold
Aug 07, 2026OppenheimerOutperformOutperformhold
Aug 07, 2026Raymond JamesStrong BuyStrong Buyhold
Jul 20, 2026BMO CapitalOutperforminitialise
Jul 20, 2026B. RileyBuyBuyhold
Jul 20, 2026H.C. WainwrightBuyBuyhold
May 06, 2026Morgan StanleyOverweightOverweighthold
Mar 09, 2026OppenheimerOutperformOutperformhold

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.29$-0.47$-0.32---
Avg Forecast$-0.31$-0.48$-0.49$-0.53$-0.53$0.02
High Forecast$-0.30$-0.46$-0.39$-0.27$-0.20$0.02
Low Forecast$-0.31$-0.49$-0.56$-0.78$-0.80$0.02
Surprise %-6.45%-2.08%-34.69%---

Revenue Forecast

$0 $20M $40M $60M $80M $100M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast---$1.10M$4.17M$98.09M
High Forecast---$1.10M$4.22M$98.09M
Low Forecast---$1.10M$4.12M$98.09M
Surprise %------

Net Income Forecast

$-80M $-63M $-46M $-29M $-12M $5M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-29.07M$-47.91M$-42.76M---
Avg Forecast$-30.21M$-47.50M$-47.05M$-65.00M$-65.45M$1.61M
High Forecast$-29.23M$-46.03M$-38.41M$-26.87M$-19.70M$1.61M
Low Forecast$-31.18M$-48.97M$-55.69M$-77.40M$-78.82M$1.61M
Surprise %-3.77%0.86%-9.12%---

TRVI Forecast FAQ

Is Trevi Therapeutics stock a buy?

Trevi Therapeutics stock has a consensus rating of Buy, based on 18 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 17 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Trevi Therapeutics is a favorable investment for most analysts.

What is Trevi Therapeutics's price target?

Trevi Therapeutics's price target, set by 18 Wall Street analysts, averages $29.67 over the next 12 months. The price target range spans from $23 at the low end to $40 at the high end, suggesting a potential 135.29% change from the previous closing price of $12.61.

How does Trevi Therapeutics stock forecast compare to its benchmarks?

Trevi Therapeutics's stock forecast shows a 135.29% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Trevi Therapeutics over the past three months?

  • October 2026: 20.00% Strong Buy, 80.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 18.18% Strong Buy, 81.82% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 18.18% Strong Buy, 81.82% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Trevi Therapeutics’s EPS forecast?

Trevi Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-0.53, marking a 65.62% increase from the reported $-0.32 in 2025. Estimates for the following years are $-0.53 in 2027, and $0.02 in 2028.

What is Trevi Therapeutics’s revenue forecast?

Trevi Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $1.1M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $4.17M, and $98.09M for 2028.

What is Trevi Therapeutics’s net income forecast?

Trevi Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-64.995M, representing an 52.00% increase from the reported $-42.759M in 2025. Projections indicate $-65.451M in 2027, and $1.61M in 2028.